SEOUL — As South Korea rapidly transitions into a super-aged society, the medical community is stepping up calls to recognize age-related hearing loss not merely as a personal inconvenience, but as a critical public health priority tied to cognitive decline and basic human rights.

Experts warn that millions of elderly citizens face financial barriers that prevent them from acquiring essential hearing aids, leaving a profound blind spot in the healthcare system that demands urgent government intervention.

These pressing policy issues took center stage at the Politzer Society Meeting (Politzer 2026 Seoul), a premier international academic event in otology and neurotology. Named after the pioneering Austrian otologist Adam Politzer, the conference brings together global specialists biennially. The Korean Otological Society co-hosted this year's gathering.

The Growing Cost of Untreated Hearing Loss

According to academic data presented at the conference, the prevalence of moderate-to-severe hearing loss rises steeply with age: 26.3% for individuals in their 70s and 52.8% for those in their 80s.

Despite this high demand, actual hearing aid adoption rates have remained stagnant at around 4.7% as of 2022, up only slightly from 2.1% in 2012. Analysts point to the heavy upfront costs of devices as the primary deterrent.

Medical authorities emphasize that leaving hearing loss unaddressed triggers far-reaching social costs. Hearing impairment is widely recognized as the single largest modifiable risk factor for dementia. Studies indicate that regular use of hearing aids can delay the onset of dementia by roughly 1.3 years, delivering cost-benefit ratios exceeding 30-fold.

To bridge this gap, the Korean Otological Society has proposed expanding pilot programs to support seniors with mild-to-moderate hearing loss who currently fall outside the official registration criteria for hearing disabilities.

In the short term, the society is pushing to legally classify hearing loss as a senior-related medical condition under the Senior Welfare Act. Over the long haul, experts aim to enact a comprehensive Hearing Health Act to streamline screening, diagnosis, rehabilitation, and follow-up care. Key initiatives include:

*Incorporating life-cycle hearing screenings into national health check-ups and community care frameworks.
*Uncovering undiagnosed cases excluded by current disability registry standards.
*Expanding National Health Insurance coverage for unilateral and asymmetrical hearing surgeries, as well as cochlear implant post-management.

"The academic society has poured considerable effort into expanding hearing aid support," said Dr. Si-Nae Park, President of the Korean Otological Society. "With recent policy discussions in the National Assembly, the outlook has brightened for small-scale pilot programs to launch within the next year or two."

Technological Breakthroughs: Gene Therapy and Robotic Cochlear Implants

Alongside these policy appeals, the conference highlighted cutting-edge technological advancements poised to revolutionize hearing restoration. However, experts stressed that these innovations will complement—rather than instantly replace—traditional rehabilitation methods.

Gene Therapy Trials: Presenting data from the CHORD clinical trial, Dr. Lawrence Lustig of Columbia University demonstrated that children receiving AAV1 vector-based therapy (DB-OTO) experienced safe hearing improvements that successfully translated into speech recognition and language development. Other international research teams introduced novel vectors (such as AAV-WM04) and global consensus guidelines for hereditary hearing loss gene therapy.
Robotic and Fully Implantable Systems: Specialists showcased advanced surgical precision technologies, including keyhole robot-assisted procedures (HEARO) and Fully Implantable Cochlear Implants (TICI). European research teams shared experiences combining ultra-low-speed electrode insertion (0.1 mm per second) with real-time electrocochleography (ECochG) monitoring to minimize cochlear trauma and preserve residual hearing.

Despite these breakthroughs, medical leaders cautioned against delaying treatment. Because critical windows for pediatric language development are narrow, families should not postpone interventions like cochlear implants while waiting for gene therapies to become universally available. Traditional devices remain the gold standard for the majority of children with auditory neuropathy spectrum disorder (ANSD).

"While hearing loss gene therapy is moving beyond theoretical potential and entering standardization phases, standard treatments like cochlear implants and hearing aids remain robustly established," noted Dr. Byung-Yoon Choi, Director of Public Relations for the society. "Rigorous academic verification and deep discussion must guide our path forward."

[Copyright (c) Global Economic Times. All Rights Reserved.]